NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run?Zacks Investment Research • 08/24/26
Is Halozyme Therapeutics (HALO) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 08/13/26
Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock UpZacks Investment Research • 08/07/26
Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 08/06/26
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass EstimatesZacks Investment Research • 08/06/26
HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCEPRNewsWire • 08/06/26
Halozyme: Unique Business Model -- Adds A Powerful Leavening Element To Any Biotech PortfolioSeeking Alpha • 07/29/26
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® TechnologyPRNewsWire • 07/20/26
Inflation Cools But US-Iran Tensions Rise: 4 Value Stocks to Buy NowZacks Investment Research • 07/16/26
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029PRNewsWire • 06/15/26
Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/10/26
Implied Volatility Surging for Halozyme Therapeutics Stock OptionsZacks Investment Research • 05/26/26